Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
End Of Schultz Era Looms For Teva
CEO Kåre Schultz Unlikely To Renew Contract Past November 2023, Company Confirms
Sep 22 2022
•
By
David Wallace
Kåre Schultz has been president and CEO of Teva since late 2017 • Source: Teva
More from Leadership
More from Generics Bulletin
